SCHEMBL6779197

SCHEMBL6779197

COc1cc(F)c(C(C)=O)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.62
CYP3A4 P08684 3/20 0.52
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
KDM4E B2RXH2 2/20 0.44
RAB9A P51151 2/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 1/20 0.43
HMGCR P04035 1/20 0.43
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43
KMT2A Q03164 2/20 0.42
PDE4A P27815 1/20 0.41
TNFSF11 O14788 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.41
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31314518 1.00 HTT (0.62) HTTCYP3A4LCKFYNKDM4E
SCHEMBL2848241 0.90 HTT (0.50) HTTCYP3A4KDM4ERAB9ALMNA
SCHEMBL1498783 0.86 HTT (0.61) HTTCYP3A4KDM4ERAB9ALMNA
SCHEMBL13927530 0.86 HTT (0.47) HTTCYP3A4KDM4ERAB9ALMNA
SCHEMBL22222472 0.85 HTT (0.46) HTTCYP3A4KDM4ERAB9ALMNA
SCHEMBL9958729 0.85 HTT (0.46) HTTCYP3A4LCKFYNRAB9A
SCHEMBL6719734 0.85 NPC1 (0.51) HTTCYP3A4KDM4ERAB9ALMNA
SCHEMBL7891214 0.85 HTT (0.50) HTTCYP3A4LCKFYNRAB9A
SCHEMBL1766160 0.83 LCK (0.60) HTTCYP3A4LCKFYNKDM4E
SCHEMBL20780495 0.82 HTT (0.43) HTTCYP3A4RAB9ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2024-02-29 US disclosed
US-11753407-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20210276999-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2021-09-09 US disclosed
US-10851101-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2020-12-01 US disclosed
EP-3406252-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2020-05-13 EP disclosed
EP-3406252-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2018-11-28 EP disclosed
EP-2812004-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2018-06-27 EP disclosed
US-20180105526-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2018-04-19 US disclosed
US-9879007-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2018-01-30 US disclosed
WO-2017161093-A1 CAFFEIC ACID DERIVATIVES AND USES THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2017-09-21 WO disclosed
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2015-01-01 US disclosed
EP-2812004-A2 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-12-17 EP disclosed
WO-2013119916-A2 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-08-15 WO disclosed
US-6703387-B2 STYRYLBENZODIAZEPINES HOFFMANN-LA ROCHE INC. 2004-03-09 US disclosed
EP-1299364-A1 BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE F. HOFFMANN-LA ROCHE AG (CH) 2003-04-09 EP disclosed
US-20020128262-A1 Inhibitors of HPV E1 helicase enzyme F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2002-09-12 US disclosed
WO-2002000632-A1 BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE F. HOFFMANN-LA ROCHE AG (CH) 2002-01-03 WO disclosed
EP-0481441-B1 Novel cephem compounds, their preparation processes and antibacterial agents KYORIN SEIYAKU KK (JP) 1996-12-11 EP disclosed
US-5244892-A Pseudomonas KYORIN PHARMACEUTICAL CO., LTD. (JP) 1993-09-14 US disclosed
EP-0481441-A2 Novel cephem compounds, their preparation processes and antibacterial agents KYORIN PHARMACEUTICAL CO., LTD. (JP) 1992-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 HTT 755/4885CYP3A4 4757/4885LCK 4832/4885
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 HTT 264/4885CYP3A4 4809/4885LCK 4802/4885
US-20180105526-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 HTT 264/4885CYP3A4 4809/4885LCK 4802/4885
US-20210276999-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 HTT 755/4885CYP3A4 4757/4885LCK 4832/4885
US-10851101-B2 Compounds for treating spinal muscular atrophy SMN1; SMN2, CPT1B, GYS1 HTT 755/4885CYP3A4 4757/4885LCK 4832/4885
US-20020128262-A1 Inhibitors of HPV E1 helicase enzyme DHX15, DHX35, DHX36 HTT 1190/4885CYP3A4 328/4885LCK 4521/4885
US-11753407-B2 Compounds for treating spinal muscular atrophy SMN1; SMN2, CPT1B, GYS1 HTT 577/4885CYP3A4 4323/4885LCK 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.